tbuckley/cabot-search huggingface dataset:
Safety of biosimilar filgrastim in patients undergoing neutropenia-inducing chemotherapy: Next study.
Authors: Frederic Maloisel, Stephane Leprêtre, Didier Kamioner, Christian Berthou, Helene Albrand
Journal: Journal of Clinical Oncology (2014)

211 Background: Febrile neutropenia (FN) is a serious, frequent complication of cytotoxic chemotherapy (CT). Biosimilar filgrastim (Nivestim, Hospira Inc.) is a granulocyte-colony stimulating factor (G-CSF) licensed for the treatment of neutropenia and FN induced by myelosuppressive CT. The NEXT (Nivestim safety profile in patients [pts] treated with cytotoxic CT in real-life clinical practice) study aimed to assess the safety of biosimilar filgrastim in pts undergoing CT for malignancies (excluding chronic myeloproliferative and myelodysplastic syndrome) and receiving biosimilar filgrastim as prophylaxis, or as curative treatment. Methods: NEXT was a prospective, non-interventional, longitudinal, multicentre study conducted in France. Recorded data included pt demographic and clinical characteristics, biosimilar filgrastim treatment-related data on efficacy and safety, such as adverse events (AEs), including FN. Pts were monitored for 1–6 CT cycles with three visits at inclusion, during treatment, and following CT. Results: Overall, 2114 pts were enrolled in the study. Of these, 2,102 pts were analysed (50.2% male). Mean age ± SD was 63.5 ± 12.7 years. 75% of pts had solid tumours and 25% had haematological malignancies. The majority (98.2%) of pts received prophylactic biosimilar filgrastim and 1.8% for curative intent. At inclusion, 92.5% of patients had no prior FN; 34.4% had prior CT; 20.2% had prior G-CSF therapy. During the study 20.4% of pts experienced ≥1 AE; AEs were reported most frequently in pts with acute leukaemia (40.0%), lymphoma (21.9%) and solid tumours (21.1%). 12.7% of pts reported bone, muscular or chest pain. 4.9% of pts experienced FN and 3.1% had an infection. Conclusions: Biosimilar filgrastim (Nivestim) was effective and well-tolerated in both the prophylactic and curative setting in pts undergoing CT for solid tumours and haematological malignancies. Biosimilar filgrastim seems to be as efficacious and as well tolerated compared with the reference filgrastim (Neupogen, Amgen) regarding retrospective data. Clinical trial information: NCT01574235.
The Selective Proteasome Inhibitor Carfilzomib Is Well Tolerated in Experimental Animals with Dose Intensive Administration
Authors: Christopher J Kirk, Jing Jiang, Tony Muchamuel, Maya Dajee, Deborah Swinarski, Monette Aujay, Mark K Bennett, Jinfu Yang, Evan Lewis, Guy Laidig, Christopher J. Molineaux
Journal: Blood (2008)
B- Prolymphocytic Leukemia Shows Heterogeneous IgVH Mutational Status and Expression of ZAP-70 and CD38.
Authors: Ilaria Del Giudice, Zadie Davis, Nnenna Osuji, Nilima Parry-Jones, Estella Matutes, Vasantha Brito-Babapulle, Andrew Wotherspoon, David Oscier, Daniel Catovsky
Journal: Blood (2004)
Role of Comorbidities in Prognostic Evaluation of Outcomes Following Allogeneic Hematopoietic Cell Transplantation (HCT) from HLA-Mismatched (MM) and Umbilical Cord Blood (UCB) Donor Grafts
Authors: Mahmoud Elsawy, Barry E. Storer, Brenda M. Sandmaier, Colleen Delaney, Frederick R. Appelbaum, Ann E Woolfrey, David G Maloney, Rainer F. Storb, Mohamed L. Sorror
Journal: Blood (2014)
Dominant negative STAT3 suppresses survival, HGF-induced motility, and invasion in malignant squamous cell carcinoma cells.
Authors: Zanobia Syed, Satish Cheepala, Weihong Yin, Jennifer Gill, John Clifford
Journal: Cancer Research (2008)

AACR Annual Meeting-- Apr 12-16, 2008; San Diego, CA

3408 

Non-melanoma skin cancer is the most common cancer in the U.S., with over a million new cases expected each year. Squamous cell carcinoma (SCC) of the skin is the most clinically aggressive form of non-melanoma skin cancer. Recent studies indicate an oncogenic role for activated STAT3, a transcription factor that regulates cell proliferation, survival, motility, as well as the local immune response. Stat3 is constitutively active in several epithelial malignancies. To address the function of STAT3 in skin SCC, SRB12-p9 cells, a highly tumorigenic human skin SCC cell line, were stably transfected with an expression construct encoding a dominant negative acting form of STAT3β (S3DN). The S3DN cells had reduced STAT3 activity and were only viable when cultured in the presence of serum, indicating a dependence on exogenous growth factors for survival (Yin et al, Molecular Cancer 5:15, 2006). In the present study we demonstrate that S3DN cells have reduced expression of survivin, an inhibitor of apoptosis that is often up-regulated during tumorigenesis and is associated with chemotherapy resistance and poor patient survival. S3DN cells exposed to a time course of serum starvation progressively lost expression of survivin, correlating with their inability to survive in serum-free media. S3DN cells also showed impaired ability to scatter upon stimulation with HGF, and diminished activity of the HGF receptor, c-Met. Interestingly, S3DN cells were able to produce larger colonies than the parental SRB12-9 cells in the soft agar colony assay, a model for anchorage-independent growth. However in mouse tumorigenicity studies, S3DN cells produced tumors that were less locally invasive than the parental cell derived tumors. The results of this study are consistent with an anti-apoptotic and invasion role for STAT3. Ongoing studies will address the effect of S3DN expression on c-Met signaling, as well as a detailed analysis of the biochemical differences between S3DN and parental tumors generated in the mouse tumorigenicity model.
Bevacizumab May Differentially Improve Ovarian Cancer Outcome in Patients with Proliferative and Mesenchymal Molecular Subtypes
Authors: Stefan Kommoss, Boris Winterhoff, Ann L. Oberg, Gottfried E. Konecny, Chen Wang, Shaun M. Riska, Jian-Bing Fan, Matthew J. Maurer, Craig April, Viji Shridhar, Friedrich Kommoss, Andreas du Bois, Felix Hilpert, Sven Mahner, Klaus Baumann, Willibald Schroeder, Alexander Burges, Ulrich Canzler, Jeremy Chien, Andrew C. Embleton, Mahesh Parmar, Richard Kaplan, Timothy Perren, Lynn C. Hartmann, Ellen L. Goode, Sean C. Dowdy, Jacobus Pfisterer
Journal: Clinical Cancer Research (2017)

Purpose: Recent progress in understanding the molecular biology of epithelial ovarian cancer has not yet translated into individualized treatment for these women or improvements in their disease outcome. Gene expression has been utilized to identify distinct molecular subtypes, but there have been no reports investigating whether or not molecular subtyping is predictive of response to bevacizumab in ovarian cancer.Experimental Design: DASL gene expression arrays were performed on FFPE tissue from patients enrolled on the ICON7 trial. Patients were stratified into four TCGA molecular subtypes. Associations between molecular subtype and the efficacy of randomly assigned therapy with bevacizumab were assessed.Results: Molecular subtypes were assigned as follows: 122 immunoreactive (34%), 96 proliferative (27%), 73 differentiated (20%), and 68 mesenchymal (19%). In univariate analysis patients with tumors of proliferative subtype obtained the greatest benefit from bevacizumab with a median PFS improvement of 10.1 months [HR, 0.55 (95% CI, 0.34-0.90), P = 0.016]. For the mesenchymal subtype, bevacizumab conferred a nonsignificant improvement in PFS of 8.2 months [HR 0.78 (95% CI, 0.44-1.40), P = 0.41]. Bevacizumab conferred modest improvements in PFS for patients with immunoreactive subtype (3.8 months; P = 0.08) or differentiated subtype (3.7 months; P = 0.61). Multivariate analysis demonstrated significant PFS improvement in proliferative subtype patients only [HR, 0.45 (95% CI, 0.27-0.74), P = 0.0015].Conclusions: Ovarian carcinoma molecular subtypes with the poorest survival (proliferative and mesenchymal) derive a comparably greater benefit from treatment that includes bevacizumab. Validation of our findings in an independent cohort could enable the use of bevacizumab for those patients most likely to benefit, thereby reducing side effects and healthcare cost. Clin Cancer Res; 23(14); 3794-801. ©2017 AACR.
Revised International Prognostic Index (R-IPI) Is a Better Predictor of Outcome Than the Standard IPI for Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Rituximab and CHOP (R-CHOP).
Authors: Laurie H. Sehn, Mukesh Chhanabhai, Catherine Fitzgerald, Karamjit Gill, Paul Hoskins, Richard Klasa, Kerry Savage, Tamara Shenkier, Judy Sutherland, Kenneth Wilson, Randy D. Gascoyne, Joseph M. Connors
Journal: Blood (2005)
Plasma Cells from Secondary Plasma Cell Leukemia Display Different Cytogenetics Pattern When Compared with Primary Plasma Cell Leukemia.
Authors: Natalia C. Gonzalez-Paz, Scott Van Wier, Rafael Santana-Davila, Gregory Ahmann, Tammy Price-Troska, Kimberly Henderson, Morie Gertz, Robert Kyle, Philip Greipp, Rafael Fonseca
Journal: Blood (2005)
Clinical Grade Ex-Vivo Expansion of Granulomonocytic Cells and Progenitors Using High-Dose SCF and G-CSF without Exhaustion of Stem Cell Activity.
Authors: Marie-Laure Bonnet, Martine Guillier, Natacha Greissinger, Marie-Catherine Marracho, Muriel Bedouel, Christian Cailliot, William Vainchenker, Catherine Boccaccio, Ali G. Turhan
Journal: Blood (2004)
EPCR/PAR1 Signaling Navigates Long-Term Repopulating Hematopoietic Stem Cell Bone Marrow Homing to Thrombomodulin-Enriched Blood Vessels
Authors: Shiri Gur Cohen, Tomer Itkin, Sagarika Chakrabarty, Claudine Graf, Orit Kollet, Karin Golan, Alexander Kalinkovich, Charles T. Esmon, Wolfram Ruf, Irit Sagi, Ayelet Erez, Tsvee Lapidot
Journal: Blood (2015)
The Bruton's Tyrosine Kinase (BTK) Inhibitor PCI-32765 Inhibits Growth of ABC DLBCL Tumors In Vivo and in Vitro by Preventing Activation of Pro-Survival NF-κB pathways
Authors: Sriram Balasubramanian, Richard Crowley, Mint Sirisawad, Patti Thiemann, Jun Chen, Joseph J. Buggy
Journal: Blood (2011)
CXCR4+ CD45− Tissue-Committed Stem Cells (TCSC) for Myocardium Reside in the Bone Marrow, Are Mobilized into the Peripheral Blood during Myocardial Infarction, and “Home” to Infarcted Myocardium in CXCR4-SDF-1 and HGF/SF-c-Met Dependent Manner.
Authors: Magda Kucia, Buddhadeb Dawn, Yiru Guo, Greg Hunt, Marcin Wysoczynski, Marcin Majka, Ewa Zuba, Francine Rezzoug, Suzanne T. Ildstad, Roberto Bolli, Mariusz Z. Ratajczak
Journal: Blood (2004)
Cytogenetic Abnormalities in Uveal Melanoma Based on Tumor Features and Size in 1059 Patients
Authors: Carol L. Shields, Emil Anthony T. Say, Murat Hasanreisoglu, Jarin Saktanasate, Brendan M. Lawson, Jeffrey E. Landy, Anjali U. Badami, Meera D. Sivalingam, Arman Mashayekhi, Jerry A. Shields, Arupa Ganguly
Journal: Ophthalmology (2017)
Specific Promoter CpG Island Methylation Patterns Identify Different Subgroups of MLL - Rearranged Infant Acute Lymphoblastic Leukemia, and Define Clinical Outcome
Authors: Dominique Jpm Stumpel, Pauline Schneider, Eddy HJ van Roon, Judith M Boer, Renee X Menezes, Rob Pieters, Ronald W. Stam
Journal: Blood (2008)
Microrna Expression Profile Identifies Distinct Clinically Relevant Sub-Groups in Multiple Myeloma: Novel Prognostic Markers and Potential Targets for Therapy
Authors: Sophia Adamia, Herve AvetLoiseau, Samirkumar B Amin, Yu-Tzu Tai, Steven P. Treon, Philippe Moreau, Stephane Minvielle, Cheng Li, Kenneth C Anderson, Nikhil C. Munshi
Journal: Blood (2008)
REAL3: A multicenter randomized phase II/III trial of epirubicin, oxaliplatin, and capecitabine (EOC) versus modified (m) EOC plus panitumumab (P) in advanced oesophagogastric (OG) cancer—Response rate (RR), toxicity, and molecular analysis from phase II.
Authors: I. Chau, A. F. C. Okines, D. Gonzalez de Castro, C. Saffery, Y. Barbachano, A. Wotherspoon, L. Puckey, S. Hulkki Wilson, F. Y. Coxon, G. W. Middleton, D. R. Ferry, T. D. L. Crosby, S. Madhusudan, J. Wadsley, J. S. Waters, M. Hall, D. Swinson, A. Robinson, D. Smith, D. Cunningham
Journal: Journal of Clinical Oncology (2011)

4131 Background: EOC is a standard treatment option for advanced OG cancer. Epidermal growth factor receptor (EGFR) overexpression is common in OG cancer and associated with poor prognosis. P is a fully-human IgG2 monoclonal antibody targeting EGFR. Prospective data on the frequency of KRAS mutations are lacking and impact on RR to chemotherapy + P in OG cancer is unknown. Due to early toxicity with EOC+P (mainly grade 3 diarrhoea), a dose-finding study recommended reduced doses of O (100mg/m2) and C (1,000mg/m2/day) in the investigational arm in combination with E 50mg/m2 and P 9mg/kg (mEOC+P) given every 3 weeks for the phase II /III study (Okines et al., J Clin Oncol 2010). Methods: Patients with histologically proven, untreated advanced OG adenocarcinoma or undifferentiated carcinoma with measurable disease and adequate end-organ function were randomised to receive up to 8 cycles of EOC or mEOC+P. RR was assessed after 4 and 8 cycles. Toxicity was assessed 3-weekly during treatment. Codon 12 and 13 KRAS mutations in the diagnostic biopsy were detected using the Therascreen KRAS mutation kit (DXS). Nineteen patients (10 mEOC+P, 9 EOC) treated in the dose finding study were excluded from this analysis. The primary endpoint of the phase II study is RR to mEOC+P. Results: Between April 09 and September 10, 200 patients were randomly allocated to EOX (n=100) or mEOC+P (n=100): Median age 62, M:F 161:39, locally advanced: metastatic 20:180, oesophageal:OGJ:gastric 83:57:60.Of the 160 patients analysed thus far, 8 (5%) had KRAS mutations in codon 12 (n=5) and codon 13 (n=3). Conclusions: Response rate, toxicity and updated molecular analysis including the frequency of KRAS, BRAF and PIK3CA mutations will be reported. 328 of the planned 730 patients have been recruited so far in this on-going study.
FIGC TERRITORIAL CENTERS: A PILOT STUDY TO DETERMINE THE LOWER LIMB STRENGTH ASYMMETRY IN YOUNG SOCCER PLAYERS
Authors: Italo Sannicandro, Vito Tisci, Antonio Quarto, Giacomo Cofano, Anna Rosa Rosa
Journal: British Journal of Sports Medicine (2017)

Background Functional asymmetry (FA) is often analyzed to reduce the young soccer players injury risk. Strength asymmetry values greater than or equal to 15% indicate a potential injury risk (Noyes et al ., 1991). Objective Describe lower limb FA values. Design Descriptive study. Setting Youth soccer. Participants 112 young soccer players (n=47 under 13 male, 12.4±0.6 yrs, 44.2±7.8 kg, 152.8±11.1 cm, BMI:17.7±0.8; n=26 under 14 male, 13.9±0.4 yrs, 56.4±8.2 kg, 168.8±8.6 cm, BMI:18.6±0.2; n=25 Under 15 female, 13.6±1.9 yrs, 49.8±6.4 kg, 159.3±6.5 cm, BMI:18.2±1.2). Inclusion criteria: no lower limb injury in the last 1 yr; soccer training age at least 3 yrs (n=15 were excluded). Interventions (or Assessment of Risk Factors) Single leg jumps, performed as Hop Test (HT), Side Hop (SH) and Triple Hop(TH) tests were used a validated marker of lower limb FA. Main Outcome Measurements Young soccer players were assessed by HT, SH, TH to evaluate strength. FA was calculated between the two limbs as follows: (jump dominant limb–jump non-dominant limb)/jump dominant-limb*100 (Yamamoto, 1993) Results FA values are shown in the table below. *indicates p&lt;0.05. Table 1 Group % FA HT % FA SH % FA TH U13 male 10.1±6.1 19.2±11.1* 9.6±6.7 U14 male 12.2±8.1 14.4±10.7 10.2±4.7 U15 female 10.8±7.2 12.3±9.4 8.4±6.5 Conclusions Monitoring of functional strength asymmetry values in the young player may help staff in reducing injury risk in youth soccer. The SH reveals s asymmetry values greater than the other two tests. The large standard deviations observed suggest that individualized preventive strategies should be adopted.
Identification of Genes Abnormally Expressed in Human MLL-AF4 Leukemia.
Authors: Shuangli Mi, Miao Sun, Zejuan Li, Roger T. Luo, Nimanthi Jayathilaka, Mary Beth Neilly, Masha Kocherginsky, Yanming Zhang, Sanggyu Lee, Theodore G. Karrison, Michael J. Thirman, San Ming Wang, Janet D. Rowley, Jianjun Chen
Journal: Blood (2006)
SURG-12THE SUB-PIAL RESECTION TECHNIQUE FOR SUPRA-MAXIMAL RESECTION OF GLIOBLASTOMAS
Authors: Yoshua Esquenazi, Elliott Friedman, Zheyu Liu, Jay-Jiguang Zhu, Sigmund Hsu, Nitin Tandon
Journal: Neuro-Oncology (2015)

BACKGROUND: Despite advances in chemotherapy and surgical approaches, the median overall survival (OS) for patients with GBM remains poor. A “supra-maximal” resection, using the sub-pial technique for low-grade gliomas aims to remove immediately proximate abnormal tissue beyond the zone of enhancement on MRI. The purpose of this study is to evaluate the feasibility and survival benefit of this technique in patients with GBM. METHODS: We retrospectively evaluated 86 consecutive patients operated on for primary GBM using the sub-pial technique with or without BCNU wafer implantation and adjuvant therapy. Presenting clinical, radiological and outcome data were collected. Multivariate Cox proportional hazards regression was used to analyze variables associated with survival. Survival was compared using Kaplan-Meier plots to stratify the impact of extent of resection (EOR) and BCNU. RESULTS: Patient age (mean) was 56 years with a 93.8% median EOR. Median OS for the group was 18.1 months and 54, 16.5 and 13.2 for GTR, NTR and STR respectively. 34.2 and 13.2 months for patients with >95% and <95% EOR. Patients undergoing NTR (p = 0.05) or GTR (p < 0.01) experienced longer survival time than patients undergoing STR as well as ≥ 95% EOR (p < 0.01) when compared to <95% EOR. BCNU had no additional advantage on survival in this cohort. CONCLUSIONS: This is the first study to evaluate the use of the sub-pial technique for resection of GBM. This technique is associated with an OS benefit not previously seen in other similar series in which resection of the enhancement portion is performed. The effect of supra-maximal resection on survival exceeded the effects of age, KPS and tumor volume at presentation. A prospective study is needed to evaluate the impact of the sub-pial technique in both quality of life and survival as compared to a traditional resection of the enhancing portion of the tumor.
Cryptogenic Stroke
Authors: Shadi Yaghi, Richard A. Bernstein, Rod Passman, Peter M. Okin, Karen L. Furie
Journal: Circulation Research (2017)

Background: Cryptogenic stroke accounts for 30% to 40% of ischemic stroke. It is essential to determine the possible culprit because this will improve secondary stroke prevention strategies. Methods: We performed a narrative nonsystematic review of the literature that included randomized trials, exploratory comparative studies, and case series on cryptogenic stroke. Results: There are several possible mechanisms implicated in cryptogenic stroke, including occult paroxysmal atrial fibrillation, patent foramen ovale, aortic arch atherosclerosis, atrial cardiopathy, and substenotic atherosclerosis. The heterogeneity of these mechanisms leads to differences in stroke prevention strategies among cryptogenic stroke patients. Conclusions: A thorough diagnostic evaluation is essential to determine the pathogenesis in cryptogenic stroke. This approach, in addition to risk factor management and lifestyle modifications, will lead to improved stroke prevention strategies in patients with cryptogenic stroke. This will allow for targeted clinical trials to improve stroke prevention strategies in this patient population.
Soluble CD30 Can Distinguish Disease Progression from Acute GVHD in Patients with Adult T Cell Leukemia/Lymphoma Who Received Allogeneic Hematopoietic Stem Cell Transplantation.
Authors: Makoto Yoshimitsu, Hiroshi Fujiwara, Noriko Aoki, Atsuo Ozaki, Heiichiro Hamada, Kakushi Matsushita, Naomichi Arima, Chuwa Tei
Journal: Blood (2006)
Validation, comparison, and combination of algorithms for automatic detection of pulmonary nodules in computed tomography images: The LUNA16 challenge
Authors: Arnaud Arindra Adiyoso Setio, Alberto Traverso, Thomas de Bel, Moira S.N. Berens, Cas van den Bogaard, Piergiorgio Cerello, Hao Chen, Qi Dou, Maria Evelina Fantacci, Bram Geurts, Robbert van der Gugten, Pheng Ann Heng, Bart Jansen, Michael M.J. de Kaste, Valentin Kotov, Jack Yu-Hung Lin, Jeroen T.M.C. Manders, Alexander Sóñora-Mengana, Juan Carlos García-Naranjo, Evgenia Papavasileiou, Mathias Prokop, Marco Saletta, Cornelia M Schaefer-Prokop, Ernst T. Scholten, Luuk Scholten, Miranda M. Snoeren, Ernesto Lopez Torres, Jef Vandemeulebroucke, Nicole Walasek, Guido C.A. Zuidhof, Bram van Ginneken, Colin Jacobs
Journal: Medical Image Analysis (2017)
Predictors of Six-Minute Walk Distance In Adults with Sickle Cell Anemia In the Walk-PHaSST Study
Authors: Robyn J. Barst, Gregory J. Kato, Vandana Sachdev, Mehdi Nouraie, Roberto F. Machado, Kathryn Hassell, Simon Gibbs, Jane Little, Dean E. Schraufnagel, Lakshmanan Krishnamurti, Reda E. Girgis, Claudia R. Morris, David B. Badesch, Sophie Lanzkron, Oswaldo Castro, Erika Berman Rosenzweig, Jonathan C. Goldsmith, Mark Gladwin, Victor R. Gordeuk
Journal: Blood (2010)
Metallothionein Reverses the Harmful Effects of Angiotensin II on the Diabetic Heart⁎⁎Editorials published in the Journal of the American College of Cardiology reflect the views of the authors and do not necessarily represent the views of JACC or the American College of Cardiology.
Authors: Walmor C. De Mello
Journal: Journal of the American College of Cardiology (2008)
CBM-08AUTOANTIBODIES FOR SPECIFIC GLIOMA ANTIGENS ARE CANDIDATE SERUM BIOMARKERS FOR EARLY DIAGNOSIS AND ADEQUATE THERAPEUTIC TARGETS
Authors: Yauso Iwadate, Masayo Adachi-Hayama, Akihiko Adachi, Tomoo Matsutani, Natsuki Shinozaki, Takaki Hiwasa, Masaki Takiguchi, Naokatsu Saeki
Journal: Neuro-Oncology (2015)

Symptomatic glioma is usually not curable due to its invasive nature into surrounding normal brain. Establishment of serum biomarkers for gliomas would be beneficial both for early diagnosis and adequate post-operative monitoring. We searched for novel glioma antigens by serological identification of antigens utilizing recombinant cDNA expression cloning (SEREX), and found three independent proteins including filamin C (FLNC), SH3-domain GRB2-like 1 (SH3GL1), and pyruvate kinase M2 (PKM2) as candidate proteins. We analyzed with ELISA 131 glioma patients' sera along with 77 sera from healthy volunteers, 19 sera from patients with meningioma, and 24 patients with cerebral infarction. All the levels of serum autoantibodies to these proteins were significantly higher in low-grade gliomas than in high-grade gliomas, the healthy volunteers and the patients with other benign disease. In contrast, these proteins were expressed in glioma tissues and its level got higher as tumor grade advanced. The discrepancy was caused by the immunosuppressive microenvironments due to mesenchymal cell infiltration, which was verified by immunohistochemistry and ELISA for the mesenchymal cell-specific proteins. The rat glioma models using C6 and 9L also confirmed the increase of autoantibody levels for the SEREX-identified proteins in the early stage and the suppression in the late stage. These proteins were involved in the oncogenic process of gliomas and effectively elicit autologous antibody responses in the glioma patients without immunosuppression. The immunological reaction to some glioma antigens would contribute to the establishment of a novel diagnostic and therapeutic target for gliomas.
The role of the extracellular matrix in primary myelofibrosis
Authors: O Leiva, S K Ng, S Chitalia, A Balduini, S Matsuura, K Ravid
Journal: Blood Cancer Journal (2017)

Abstract Primary myelofibrosis (PMF) is a myeloproliferative neoplasm that arises from clonal proliferation of hematopoietic stem cells and leads to progressive bone marrow (BM) fibrosis. While cellular mutations involved in the development of PMF have been heavily investigated, noteworthy is the important role the extracellular matrix (ECM) plays in the progression of BM fibrosis. This review surveys ECM proteins contributors of PMF, and highlights how better understanding of the control of the ECM within the BM niche may lead to combined therapeutic options in PMF.